Cinctive Capital Management LP Sells 78,272 Shares of Edwards Lifesciences Corporation $EW

Cinctive Capital Management LP lowered its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 50.1% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 77,956 shares of the medical research company’s stock after selling 78,272 shares during the quarter. Cinctive Capital Management LP’s holdings in Edwards Lifesciences were worth $6,063,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the stock. Level Four Advisory Services LLC grew its position in Edwards Lifesciences by 3.7% in the third quarter. Level Four Advisory Services LLC now owns 3,301 shares of the medical research company’s stock worth $257,000 after acquiring an additional 119 shares in the last quarter. Colonial Trust Co SC raised its position in Edwards Lifesciences by 0.4% during the third quarter. Colonial Trust Co SC now owns 32,196 shares of the medical research company’s stock valued at $2,504,000 after purchasing an additional 120 shares in the last quarter. Howard Capital Management Inc. raised its position in Edwards Lifesciences by 3.3% during the third quarter. Howard Capital Management Inc. now owns 4,136 shares of the medical research company’s stock valued at $322,000 after purchasing an additional 132 shares in the last quarter. Empirical Finance LLC lifted its stake in Edwards Lifesciences by 0.6% during the second quarter. Empirical Finance LLC now owns 21,329 shares of the medical research company’s stock worth $1,668,000 after purchasing an additional 134 shares during the last quarter. Finally, Alpine Bank Wealth Management boosted its holdings in shares of Edwards Lifesciences by 10.7% in the 3rd quarter. Alpine Bank Wealth Management now owns 1,392 shares of the medical research company’s stock worth $108,000 after purchasing an additional 135 shares in the last quarter. 79.46% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

EW has been the topic of several recent research reports. Canaccord Genuity Group set a $87.00 price objective on Edwards Lifesciences and gave the company a “hold” rating in a research report on Wednesday, December 17th. UBS Group restated a “neutral” rating and issued a $94.00 target price on shares of Edwards Lifesciences in a research report on Wednesday, February 4th. Royal Bank Of Canada upped their target price on Edwards Lifesciences from $95.00 to $100.00 and gave the stock an “outperform” rating in a research note on Friday, December 5th. TD Cowen upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a research report on Friday, January 9th. Finally, Evercore reissued an “outperform” rating and set a $94.00 price target on shares of Edwards Lifesciences in a research note on Monday, January 5th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $96.14.

Edwards Lifesciences Stock Down 3.3%

EW opened at $81.82 on Friday. Edwards Lifesciences Corporation has a 12 month low of $65.94 and a 12 month high of $87.89. The company has a current ratio of 3.72, a quick ratio of 3.09 and a debt-to-equity ratio of 0.06. The business’s 50-day moving average price is $82.41 and its 200-day moving average price is $81.58. The company has a market cap of $47.52 billion, a P/E ratio of 44.71, a P/E/G ratio of 2.13 and a beta of 0.93.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing the consensus estimate of $0.62 by ($0.04). The company had revenue of $1.57 billion for the quarter, compared to analysts’ expectations of $1.54 billion. Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The company’s revenue was up 13.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.59 earnings per share. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, equities analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insider Activity

In related news, CFO Scott B. Ullem sold 13,000 shares of the company’s stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $84.92, for a total transaction of $1,103,960.00. Following the completion of the sale, the chief financial officer directly owned 39,699 shares in the company, valued at $3,371,239.08. This represents a 24.67% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, VP Daniel J. Lippis sold 1,019 shares of the stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $85.38, for a total transaction of $87,002.22. Following the sale, the vice president directly owned 33,934 shares of the company’s stock, valued at $2,897,284.92. The trade was a 2.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 61,718 shares of company stock valued at $5,236,281. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.